Watch for Some Gout Patients to Switch From Uloric to Allopurinol

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You may get fewer Rxs for febuxostat (Uloric) for gout...due to concerns it increases risk of death.

Patients with gout are already at elevated cardiovascular risk.

Now febuxostat is under fire due to recent studies suggesting it may cause more cardiovascular deaths than allopurinol in some patients.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote